药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Ginkgo biloba
Aluminium clofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ubidecarenone is combined with Aluminium clofibrate.
Ginkgo biloba
Ronifibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ubidecarenone is combined with Ronifibrate.
Ginkgo biloba
Simfibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ubidecarenone is combined with Simfibrate.
Ginkgo biloba
Emetine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ubidecarenone is combined with Emetine.
Ginkgo biloba
Ipecac
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ubidecarenone is combined with Ipecac.
Ginkgo biloba
Mebeverine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ubidecarenone is combined with Mebeverine.
Ginkgo biloba
Tianeptine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ubidecarenone is combined with Tianeptine.
Ginkgo biloba
Ciprofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Ubidecarenone.
Ginkgo biloba
Acipimox
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Ubidecarenone.
Ginkgo biloba
Etofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Etofibrate is combined with Ubidecarenone.
Ginkgo biloba
Raltegravir
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Ubidecarenone.
Ginkgo biloba
Trabectedin
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trabectedin is combined with Ubidecarenone.
Ginkgo biloba
Piperine
The serum concentration of Ubidecarenone can be increased when it is combined with Piperine.
Ginkgo biloba
Mevastatin
The risk or severity of myopathy and rhabdomyolysis can be decreased when Ubidecarenone is combined with Mevastatin.
Ginkgo biloba
(S)-Warfarin
The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Ubidecarenone.
Ginkgo biloba
Tioclomarol
The therapeutic efficacy of Tioclomarol can be decreased when used in combination with Ubidecarenone.
Ginkgo biloba
Diphenadione
The therapeutic efficacy of Diphenadione can be decreased when used in combination with Ubidecarenone.
Ginkgo biloba
Clorindione
The therapeutic efficacy of Clorindione can be decreased when used in combination with Ubidecarenone.
Ginkgo biloba
Fluindione
The therapeutic efficacy of Fluindione can be decreased when used in combination with Ubidecarenone.
Ginkgo biloba
Ethyl biscoumacetate
The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Ubidecarenone.